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Summary
Mutations in PRPF31 are responsible for autosomal dominant retinitis pigmentosa (adRP, RP11 form) and affected
families show nonpenetrance. Differential expression of the wildtype PRPF31 allele is responsible for this phenomenon:
coinheritance of a mutation and a higher expressing wildtype allele provide protection against development of disease.
It has been suggested that a major modulating factor lies in close proximity to the wildtype PRPF31 gene on Chromosome
19, implying that a cis-acting factor directly alters PRPF31 expression. Variable expression of CNOT3 is one determinant
of PRPF31 expression. This study explored the relationship between CNOT3 (a trans-acting factor) and its paradoxical
cis-acting nature in relation to RP11.
Linkage analysis on Chromosome 19 was performed in mutation-carrying families, and the inheritance of the wildtype
PRPF31 allele in symptomatic–asymptomatic sibships was assessed—confirming that differential inheritance of wildtype
chromosome 19q13 determines the clinical phenotype (P < 2.6 × 10−7).
A theoretical model was constructed that explains the apparent conflict between the linkage data and the recent demon-
stration that a trans-acting factor (CNOT3) is a major nonpenetrance factor: we propose that this apparently cis-acting
effect arises due to the intimate linkage of CNOT3 and PRPF31 on Chromosome 19q13—a novel mechanism that we
have termed “linked trans-acting epistasis.”
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Introduction
It has long been recognized that a disease-causing mutation
can have different effects in different individuals and this may
be due to environmental factors, stochastic molecular vari-
ation, epigenetic variation between individuals, or epistatic
interactions (Nabholz & von Overbeck, 2004; Fraga et al.,
2005; Raj & van Oudenaarden, 2008). Epistasis is the phe-
nomenon whereby the phenotype caused by a mutation (or
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polymorphism) is masked by an allele at another locus, hence
the alternative use of the terms gene–gene or genetic inter-
action. Although epistasis was first described over 100 years
ago, it has received relatively little attention, in part due to
our limited knowledge of epistatic mechanisms at a molec-
ular level, and also due to our almost nonexistent ability to
predict epistatic interactions de novo (Bateson, 1909; Lehner,
2011). It is clear, however, that epistasis is a pervasive phe-
nomenon, having been reported to determine the phenotypic
outcome of genetic variations in all sorts of organisms, includ-
ing plants, invertebrates, (e.g., flies) and vertebrates (e.g., birds,
mammals) (Montooth et al., 2003; Kroymann & Mitchell-
Olds, 2005; Carlborg et al., 2006; Shao et al., 2008). Several
molecular mechanisms can underlie epistasis, including direct
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interaction between the protein products of the genes, func-
tional redundancy, involvement of the two genes in a common
pathway or interaction between separate molecular pathways
(Lehner, 2011). A further possibility is that epistatic interac-
tions affect the regulatory network of genes. The multifaceted
nature of gene expression regulation means that epistatic in-
teractions are frequent and complex, although this idea has
not been explored in great detail to date (Carter et al., 2007;
Gertz et al., 2010).
Retinitis pigmentosa (RP) is a genetically heterogenous
group of retinal degenerations, characterized by progressive
cell death of the rod photoreceptors. Autosomal dominant
retinitis pigmentosa (adRP) accounts for approximately 30–
40% of cases and causative mutations have been identified in
over 20 genes. Amongst these is an unusual class of causative
genes—the splicing factors—six of which have been defined
as causative of adRP (McKie et al., 2001; Vithana et al., 2001;
Chakarova et al., 2002; Keen et al., 2002; Zhao et al., 2009;
Tanackovic et al., 2011a).
Mutations in the ubiquitous splicing factor PRPF31 were
found to underlie a major RP locus, termed RP11 (Al-
Magtheth et al., 1996; Vithana et al., 2001). PRPF31 protein
plays a key role in the process of mRNA splicing, through its
interaction with theU4/U6.U5 tri-snRNP—the key ribonu-
cleoprotein complex of both major and minor spliceosomes.
The PRPF31 protein contains a Nop domain that allows
binding of the U4 snRNP within the U4/U6 di-snRNP
(Liu et al., 2007). PRPF31 then links the U4/U6 di-snRNP
with the U5 snRNP to form the U4/U6.U5 tri-snRNP, this
process being mediated by the binding of PRPF6 by PRPF31
(Weidenhammer et al., 1997; Makarova et al., 2002; Liu et al.,
2006). RNA interference mediated knockdown of PRPF31
expression inhibits formation of tri-snRNPs, with accumu-
lation of U4/U6 di-snRNPs in the Cajal bodies (Schaffert
et al., 2004).
Mutations in PRPF31 are a relatively common cause of
adRP, accounting for approximately 5–10% of cases (Waseem
et al., 2007; Audo et al., 2010; Xu et al., 2012). Over 40
mutations have been identified to date, including nonsense,
missense, and frameshift mutations, as well as large deletions
(Audo et al., 2010; Utz et al., 2013). Most PRPF31mutations
result in null alleles, either through complete or partial ab-
sence of gene (large deletions) or throughmRNA that quickly
undergoes degradation (Rio Frio et al., 2008a; Audo et al.,
2010). Carriers of such mutations can, therefore, be consid-
ered to be functional hemizygotes (Rio Frio et al., 2008a;
Audo et al., 2010). There has been one report of functional
haploinsufficiency, where a single base pair deletion within
the PRPF31 promoter region reduced transcription of the
gene (Rose et al., 2012).
One interesting aspect of RP11 is that, although PRPF31
is essential for splicing in all cells, the disease phenotype is
retina-specific but this is not due to the existence of retina-
specific isoforms of PRPF31 (Tanackovic & Rivolta, 2009).
In patients carrying PRPF31 mutations, there is a generalized
defect in spliceosome assembly and pre-mRNA processing
and, as the retina has a particularly high requirement for pre-
mRNA splicing, it was suggested that retina—as compared
to other tissues—is relatively more affected by mutations of
splicing factors (Tanackovic et al., 2011b).
Another consistent feature of PRPF31-associated adRP
(RP11) is phenotypic nonpenetrance, whereby an asymp-
tomatic individual carrying a mutant allele can have affected
siblings or children. It is known that nonpenetrance is de-
termined by the expression level of the wildtype PRPF31
allele, and that there is variable expression of the PRPF31
gene in the general population (Rio Frio et al., 2008a). It has
been shown that asymptomatic mutation carriers have more
than twofold higher expression levels of wildtype PRPF31
compared to symptomatic individuals (Vithana et al., 2003;
Rivolta et al., 2006; Liu et al., 2008). Patients coinheriting a
PRPF31 mutant and a higher expressing wildtype allele are
asymptomatic because the residual level of protein is still suf-
ficient for normal retinal function—the wildtype allele is able
to compensate for the mutant allele.
McGee et al. (1997) looked at phenotypic discordance
between mutation-carrying siblings and observed that the
affected siblings and unaffected siblings consistently inher-
ited different wildtype Chromosome 19q13 alleles from the
nonmutation-carrying parent. It is generally thought, there-
fore, that a cis-acting factor that directly alters wildtype
PRPF31 expression is responsible for the observed phenotypic
nonpenetrance. Attempts to identify single nucleotide poly-
morphisms (SNPs) that might be responsible for altered gene
expression have failed to identify any causative changes. One
theory draws attention to the high-repeat content of Chro-
mosome 19 and proposes that variability in repeat elements,
such as Alu repeats, might play a role (Rose et al., 2011).
Another interesting aspect of this disease is that, prior to
nonsense-mediated decay of the mutant PRPF31, there is
increased expression of both PRPF31 alleles in mutation-
carrying asymptomatic individuals (Rio Frio et al., 2008a). As
there is some increased expression of both the wildtype and
mutant alleles of PRPF31, there must be at least one factor that
is trans-acting. One possible trans-acting factor was identified
through the association of higher PRPF31 expression and an
expression quantitative trait locus (eQTL) at 14q21–23 (Rio
Frio et al., 2008b).
It has also been shown that PRPF31 expression level is in-
fluenced byCNOT3, with increased levels of CNOT3 protein
causing transcriptional repression of PRPF31 (Venturini et al.,
2012). CNOT3 is a component of the Ccr4-Not transcription
complex, which is an evolutionarily conserved global regu-
lator of RNA polymerase II-mediated transcription (Miller
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& Reese, 2012). An inverse relationship has been shown be-
tween PRPF31 expression and CNOT3 mRNA levels, and
siRNA-mediated silencing of CNOT3 provoked an increase
in PRPF31 expression, these observations further confirm the
repressive nature of the interaction (Venturini et al., 2012).
This paper explores an apparent paradox in the relationship
between PRPF31 and CNOT3: This paradox arises when
trying to reconcile (i) the current knowledge that a cis-acting
factor in close proximity of PRPF31 is the major factor un-
derlying nonpenetrance (McGee et al., 1997), whereas (ii) the
trans-acting CNOT3 appears to be one of the major factors
controlling PRPF31 expression (Venturini et al., 2012).
Methods
Two approaches were taken to address this paradox.
First, the conjecture of McGee et al. was reviewed—in
which they suggest that inheritance of the wildtype allele of
Chromosome 19q13.4 is responsible for determining pheno-
type in carriers of the PRPF31mutation (McGee et al., 1997).
This was tested with the null hypothesis that, for mutation-
carrying siblings, the wildtype gene is randomly inherited
from the nonmutation-carrying parent and, therefore, each
haplotype from the unaffected parent is equally represented
in the “symptomatic” and “asymptomatic” offspring within
a given sibship.
To test the null hypothesis, previously collected microsatel-
lite linkage data from six families (AD5, AD11, AD24, AD29,
ADC1, RP1907) were reanalyzed to examine the inheritance
of the wildtype Chromosome 19q13 (Al-Maghtheh et al.,
1996; Vithana et al., 1998; Abu-Safieh, 2003; Rose et al.,
2012). Microsatellite data were also collected from one fur-
ther family (ADB1), in which a PRPF31 mutation had pre-
viously been identified, but without performance of link-
age analysis (Chakarova et al., 2006). The genotype data for
mutation-carrying siblings were phased before consideration
of the wildtype gene: The left-hand-most (oldest) mutation-
carrying sibling of each branch was treated as the reference
wildtype haplotype; if they were symptomatic they were as-
signed “green,” if they were asymptomatic they were assigned
“orange.” The wildtype allele in the remaining siblings was
analyzed, and classed as being concordant with the reference
haplotype or nonconcordant. Where meiotic recombination
had occurred, the sibling was regarded as concordant if half
or more of the markers were identical.
Second, a theoretical model was proposed to explain the
relationship between CNOT3 and PRPF31 mutations, this
model reconciling how a known trans-acting factor (CNOT3)
could be a major nonpenetrance factor and yet be consistent
with a “wildtype inheritance” theory that appears to require
a direct cis-acting mechanism.
Microsatellite Analysis
The inheritance of the wildtype chromosome 19q13 was an-
alyzed in individuals from unrelated families carrying known
mutations in PRPF31, each individual being required to have
at least one mutation-carrying sibling. All families had evi-
dence of nonpenetrance, with both symptomatic and asymp-
tomatic mutation carriers within sibships. The inheritance of
the wildtype Chromosome 19q13 was analyzed for six such
families (AD5, AD11, AD24, AD29, ADC1, RP1907) by re-
examination of previously collected microsatellite linkage data
(Al-Maghtheh et al., 1996; Vithana et al., 1998; Abu-Safieh,
2003; Rose et al., 2012) and by linkage analysis of microsatel-
lite data for one further mutation-carrying family (ADB1)
(Chakarova et al., 2006). The microsatellite markers covered
the region surrounding PRPF31 and CNOT3 on Chromo-
some 19q13, this region including markers between D19s921
and D19S418 (Chromosome 19:53771240–55546128). Ad-
ditional markers to north or south of this region were analyzed
where data were available (Fig. 1).
To perform linkage analysis in family ADB1, ABI PRISM
Linkage Mapping Set (Applied Biosystems, Paisley, UK) was
used, using only the primers for the region of interest on
Chromosome 19q13 (Fig. 1). The following procedure was
used: 5-μl Absolut qPCR mix (Thermoscientific, Lougbor-
ough, UK) was combined with 1-μl genomic DNA, 300-μM
primer (forward/reverse), and distilled water to a total volume
of 10 μl. The mixture was denatured at 94◦C for 15 min, fol-
lowed by 30 cycles of 94◦C, 15 s; 60◦C, 30 s; 72◦C, 30 s.
Finally, the mixture was held at 72◦C for 5 min. The product
was then diluted by combining 1-μl PCR product with 11-μl
HiDi formamide (Applied Biosystems) and 0.1-μl GeneScan
500 Liz Size Standard (Invitrogen, Paisley, UK). The mixture
was denatured for 5 min at 95◦C, then incubated on ice for
2 min. The sample was genotyped on ABI 3730 and
the results analyzed using GeneMarker v1.8 (Softgenetics,
Pennsylvania, USA). The marker primers used were from ABI
Prism Linkage mapping set v2.5 (Applied Biosystems).Where
possible, previously collected data were validated, using the
same methods as described in the original manuscripts.
Statistical and Bioinformatic Analyses
The reference sibling was excluded from the dataset and the
null hypotheses assessed using Fisher’s exact test.
Polymorphism data was obtained from Ensembl (http://
www.ensembl.org, hg19 genome sequence) and dbSNP
databases (http://www.ncbi.nlm.nih.gov/SNP). Pathogenic-
ity of nonsynonymous SNPs was analyzed using stan-
dard parameters in Polyphen (http://genetics.bwh.harvard.
edu/pph2/) and Sift (http://sift.bii.a-star.edu.sg/).
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Figure 1 Marker map showing the relative position of markers used in linkage analysis (blue), PRPF31 (green), and CN0T3 (red).
The regions covered in each family are shown by the orange boxes below, with the core region containing both genes of interest
(D19s921-D19s418; chr19:53771240–55546128) being examined in all families.
Results
Microsatellite data were derived for six members of fam-
ily ADB1 (Fig. S1) and this, together with previously de-
rived data from other unrelated families, provided data for 53
individuals—both symptomatic and asymptomatic (Fig. 2).
The inheritance pattern shows a very highly significant devi-
ation from the null hypothesis (χ2 = 21.5; P = 2.6 × 10−7)
(Table 1).
Discussion
The highly concordant—rather than random—inheritance of
the wildtype allele in mutation-carrying sibships (Table 1) in-
dicates that the factor controlling the clinical manifestations
of the PRPF31 mutation must be cis-acting. This is a neces-
sary conclusion because, if it was trans-acting, the controlling
allele could reside on either Chromosome 19 (or, indeed, any
other chromosome) and thereby determine phenotype (Figs
3A and B): under these circumstances the inheritance of wild-
type Chromosome 19 would be random and independent of
phenotype—which is manifestly not the case (Table 1).
The simplest cis-acting factor would be one that directly
affects the expression of the PRPF31wildtype allele (Fig. 3C).
Alternatively, there might be a cis-acting factor that affects
another gene lying immediately upstream to PRPF31 and
which cannot, therefore, be separated by recombination—an
“indirect cis-acting” element.
CNOT3 and PRPF31: An Apparent Paradox?
The only known nonpenetrance factor affecting the RP11
phenotype is transcriptional repression of PRPF31 by
CNOT3, the latter being a trans-acting factor (Venturini et al.,
2012). Furthermore, there is increased expression of both
the mutant and wildtype PRPF31 alleles prior to nonsense-
mediated decay of the mutant transcripts (Rio Frio et al.,
2008a), and this necessitates at least one nonpenetrance factor
which is trans-acting—again, this observation being compati-
ble with a CNOT3 control mechanism. An apparent paradox
appears to exist between this known, trans-acting control of
PRPF31 expression by CNOT3, and the results of our study
that implicate a mechanism which is cis-acting. This paradox
can, however, be resolved if a trans-acting factor lies in close
proximity to its target gene—in this case, PRPF31—and is
therefore not separated by meiotic recombination (Fig. 3D).
Such a factor, although working through a trans-acting mech-
anism, would appear to be cis-acting because of its linkage and
proximity to the target gene—a mechanism that might use-
fully be termed “linked trans-acting epistasis.”
In the case of RP11, it is known that the trans-acting
CNOT3 gene is located only a short distance from PRPF31
and the two genes are effectively linked during meiotic re-
combination. This linkage renders their epistatic interaction
equivalent to a cis-acting mechanism (Fig. 3D) and we con-
sider it likely that differential CNOT3 expression is the trans-
acting factor that modulates expression of both PRPF31 al-
leles, but with degradation of the mutant PRPF31 mRNA
(Rio Frio et al., 2008a).
A New Conjectural Model for “Linked
Trans-Acting Epistatic” Inheritance
In the context of CNOT3 control and PRPF31 mutations,
this novel “linked trans-acting epistatic” model of inheritance
leads to some further theoretical consequences: First, it is
known that lower expression of CNOT3 leads to higher ex-
pression of PRPF31, and vice-versa (Venturini et al., 2012).
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Figure 2 Inheritance of the wildtype allele of Chromosome 19 in seven families
carrying a mutation in PRPF31. In each group of siblings, the oldest
mutation-carrying sibling (asterisked) acts as reference wildtype and was denoted
orange if symptomatic or green if asymptomatic. The other mutation-carrying siblings
were then assigned a concordant color triangle if they inherited the same wildtype
allele as the reference sibling, or a discordant color triangle if they inherited the
different wildtype allele to the reference sibling. “A” represents family AD5–1; B =
AD5–2; C = AD11; D = AD24; E = AD29; F = RP1907; G = ADB1; H = ADC1.
Table 1 The Nonreference Siblings were Counted and Classified as Asymptomatic or Symptomatic and Concordant or
Nonconcordant—The Latter with Respect to the Reference Sibling (the Oldest Mutation Carrier). The Expected Values were Calculated
Assuming Random Inheritance of Chromosome 19q—in which Case, there would be Equal Numbers of Concordant and Nonconcordant
for both Asymptomatic and Symptomatic Individuals.
Concordance of genotype with that of reference sibling
Observed concordance Expected concordance
Concordant Nonconcordant Concordant Nonconcordant
Symptomatic 2 16 9 9
Asymptomatic 14 0 7 7
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Figure 3 Four mechanisms for modulation of the expression
of PRPF31. (A) Nonsyntenic modulation: there is a
trans-acting factor (purple diamond) being transcribed from
another chromosome (i), this binding to an element on
Chromosome 19 (ii), and thereby modulating the expression of
PRPF31 (iii). This mechanism is not compatible with the
observed nonrandom inheritance of wildtype alleles. (B)
Distant modulation on Chromosome 19: a mechanism similar
to (A) applies to a hypothetical trans-acting factor transcribed
from a remote part of Chromosome 19. As the remote,
controlling gene is liable to be separated from the PRPF31
mutation during meiotic recombination, inheritance of the
wildtype Chromosome 19 and the trans-acting factor are,
effectively, independent. This mechanism is not compatible
with the observed nonrandom inheritance of wildtype alleles.
(C) “Direct cis-effect”: there is a cis-element (pink) that lies in
close proximity to PRPF31 (i), this then being bound by a
transcription factor (pink diamond), and the interaction
directly affects PRFP31 expression level (ii). This mechanism is
compatible with the observed nonrandom inheritance of
wildtype alleles. (D) “Linked trans-effect”: there is a cis-element
(turquoise) linked in close proximity to the PRPF31 gene, such
that the two are not separated by recombination (i). The
cis-acting element causes differential expression of CNOT3
In any mutation-carrying individual, there will be a higher or
lower expressing CNOT3 allele syntenic to the PRPF31 mu-
tation, and a higher or lower expressing one syntenic to the
wildtype PRPF31 (Fig. 4). In reality, as polygenic factors act
to determine expression of the two genes, there will be a con-
tinuum of expression level at a population level. There will,
however, be a threshold—above which the level is considered
“high” and below which the level is considered “low.” With
this in mind, it is possible to construct a simplified model.
Linkage analysis has shown that the CNOT3 and PRPF31
loci are not separated by recombination, and so the mutation-
carrying chromosome will always carry the same syntenic
CNOT3 allele; the PRPF31 mutation will be linked either to
a “lower expressivity” or to a “higher expressivity” CNOT3
allele (Fig. 4). A necessary consequence is that, for any given
sibship with two parents, individuals can only fall into one of
two groupings—either “A” and “B,” or else “C” and “D”
(Fig. 4); for example, it is not possible for siblings to have
genotypes “A” and “D.” Further to this inference, the phe-
notypic difference between symptomatic and asymptomatic
siblings can only be attributed to a difference in the CNOT3
allele linked to the wildtype PRPF31 allele.
Considering the four possible genotypes (Fig. 4), expres-
sion of CNOT3 is the same for individuals “B” and “C”
and, as CNOT3 is trans-acting, this would result in similar
PRPF31 expression and, therefore, the same phenotype. It
needs to be considered what the phenotype of “B + C”
individuals is: asymptomatic or symptomatic? It is clear that
“B + C” individuals cannot be symptomatic, as this would
lead symptomatic “C + D” siblings pairs who inherit differ-
ent wildtype alleles—which we have demonstrated does not
occur. It must be the case, therefore, that “B + C” individuals
are asymptomatic.
Further to the deduction of all affected families being in
the “C+D” group, it is therefore necessary for symptomatic
individuals to have two copies of a higher expressing CNOT3
allele (that is, a homozygous recessive inheritance).
With this assumption in mind, it is possible to predict
an approximate frequency of CNOT3 alleles within the
(blue diamonds; larger size indicating transcription from a
higher expressed allele) (ii), this thereby modulating the
expression of both the mutant and wild-type PRPF31 alleles
(iii). This situation is compatible with the observed inheritance
pattern of wildtype alleles, as long as the cis-element (turquoise)
and PRPF31 are not separated during meiotic recombination.
The hypothetical trans-acting factor would bind and activate
both PRPF31 copies, but only the wildtype allele is
functionally expressed—as PRPF31 mutations generally result
in null alleles (that is, large deletions or nonsense alleles that are
immediately degraded; Rio Frio et al., 2008a).
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Table 2 Ensembl and dbSNP Report Three Nonsynonymous SNPs as Rare Normal Variants within the Coding Region of the PRPF31
Gene, these being Predicted to be Pathogenic by both Sift and Polyphen. This Raises the Issue that these Rare Changes might be
Pathogenic on a Different Genetic Background.
SNP Exon Change Sift Polyphen Heterozygote frequency
rs150280707 6 p.Val169Ile 0.1 0.946 <0.0001
rs119475042 7 p.Ala216Thr 0 1 <0.0001
rs151337240 13 p.Ala453Asp 0 0.999 0.001
Figure 4 Combinations of CNOT3 genotype in patients
carrying the PRPF31 mutation. The L indicates a
low-expressing CNOT3 allele—which, due to the repressive
nature of the interaction, leads to high level of PRPF31
expression. The H indicates a high-expressing CNOT3, which
leads to lower level of PRPF31. Sibling pair “A + B” carries a
PRPF31 mutation with a syntenic low-expressing CNOT3 (L),
whereas sibling pair “C + D” carries a syntenic high-expressing
CNOT3 (H). Because of the intimate linkage of CNOT3 and
PRPF31, these alleles are effectively locked together during
meiotic recombination—this dictating that all individuals from
a given sibship will be either “A + B,” or else “C + D.” The
level of CNOT3 protein in individuals “B” and “C” is
identical, and they would therefore be expected to have the
same asymptomatic phenotype. They cannot both be
symptomatic, as the “C + D” sibling pair would be
incompatible with the observed nonrandom inheritance of the
wildtype allele. Individual “A” should also be unaffected,
having the lowest levels of CNOT3 (with correspondingly
highest level of PRPF31). The most important conclusion of
this inheritance model is that the only symptomatic individual
(“D”) inherits two high-expressing CNOT3 alleles—there is
homozygous, recessive inheritance of the CNOT3 trait.
population, given that approximately 30% of mutation carriers
are asymptomatic. Using standard Hardy–Weinberg equilib-
rium, we can predict that 83.7% of CNOT3 haplotypes lead
to higher expressing alleles (which when inherited recessively
lead to disease) and the remaining 16.3% of haplotypes lead
to lower expressing alleles, with a level of CNOT3 above our
theoretical threshold. This is, of course, a gross oversimplifi-
cation, as it assumes that CNOT3 is the only factor affecting
PRPF31.
A further necessary deduction from this hypothesis is
that mutation-carrying families can occur with absolutely
no clinically affected individuals, despite harboring PRPF31
mutations (entirely “A and B” sibling pairs). As such
families are clinically normal, they will never present to
medical attention unless a meiotic recombination affecting
the CNOT3–PRPF31 interzone occurs on the mutation-
carrying chromosome—this being a remotely improbable
event given the tight linkage between CNOT3 and PRPF31.
To prove the existence of such “A and B” families would be
arduous: RP affects 0.03% people, of which adRP accounts
for 60%, and PRPF31 mutations account for less than 10%
of adRP cases—the population prevalence therefore being
about 0.002%. To find a completely asymptomatic mutation-
carrying (“A + B”) family would require screening of a vast
number of control individuals. It is possible, however, that
some of the rare changes reported in the reference databases
are mutations—but on a genetic background that masks the
clinical phenotype: For example, there are three nonsynony-
mous coding region SNPs within the PRPF31 coding se-
quence that both Sift and Polyphen predict to be deleterious
(Table 2).
Conclusions
Coinheritance of a heterozygous PRPF31 mutation and a
homozygous higher expressivity variant of CNOT3 appears
to determine the clinical presentation of RP11, this being a
classic example of epistasis, where a disease mutation is masked
by genetic interaction with a second locus. In this case, a
mutation in PRPF31 is hypostatic to a trait acting onCNOT3,
with the RP11 phenotype only being observed when there is
homozygous (recessive) inheritance of the higher expressivity
CNOT3 (“symptomatic” or risk) allele.
Traditionally, genetic disease has been split into two
groups—“Mendelian” and “complex”—but this is a gross
oversimplification. PRPF31-associated adRP can usefully
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be thought of as a “hybrid” genetic disease, with fea-
tures of Mendelian and complex disorders: primarily, there
is a PRPF31 gene mutation (the monogenic “Mendelian”
component)—and, superimposed on this, there is polygenic
control of expression of the remaining, genetically active
wildtype PRPF31 gene—the “complex” component of the
disorder.
Nonpenetrant traits have previously been largely regarded
as monogenic, this greatly hindering research as most investi-
gations have sought “all-or-nothing” phenomena. As shown
in this study, it appears more appropriate to investigate pheno-
typic nonpenetrance as a polygenic trait, with interaction of
major risk alleles (such as repression by CNOT3) and a num-
ber of minor alleles to determine the overall level of PRPF31
expression and, consequentially, the clinical manifestation of
the monogenic mutation. It should also be noted that given
the continuous nature of PRPF31 expression in the popula-
tion, some mutation carriers will be “nearer” the threshold
for normal retinal function and hence will have milder dis-
ease presentation. One might foresee the ability to quantify
the odds ratios for such risk factors and—based upon the
genome—produce a predictive model for development of the
disease.
Although control ofCNOT3 expression has been discussed
as if a single entity, it should be emphasized that this, too, is
multifactorial with cis-acting factors on Chromosome 19q13
affecting CNOT3 expression; such factors being within core
promoter, intronic regulatory, or long-range regulatory ele-
ments. These factors will produce a haplotype that has a cu-
mulative effect on CNOT3, seen as a continuous distribution
of CNOT3 expression level in the population.
Based on the evidence that approximately 30% of muta-
tion carriers are asymptomatic, we predicted that approxi-
mately 16% of haplotypes result in CNOT3 level that is lower
than the theoretical threshold. It should be noted, however,
that in some populations the frequency of asymptomatic mu-
tation carriers is significantly lower than the average—for
example, based on recent data in Chinese families, approxi-
mately 5% of mutation-carrying family members were asymp-
tomatic (Xu et al., 2012; Yang et al., 2013). In these popula-
tions, the lower expressingCNOT3 haplotypes would be very
rare.
Several SNPs—such as rs4806718—lie close to, or within,
the CNOT3–PRPF31 region and correlate with the pheno-
type of some, but not all, sibling groups (unpublished data;
Venturini et al., 2012); the importance of SNPs should, how-
ever, be viewed with caution until their functional effect
has been demonstrated. Functional polymorphisms within
the regulatory elements of both PRPF31 and CNOT3
might have a combined effect to determine the overall
expression level of PRPF31. Likewise, trans-acting factors
from other chromosomes—such as the eQTL described on
Chromosome 14 (Rio Frio et al., 2008b)—might modulate
PRPF31 and CNOT3 expression.
Identification of all polymorphisms with a role in the
CNOT3–PRPF31 regulatory network is daunting: It would
be necessary to sequence the 19q13 region in a large cohort
of control individuals with predetermined expression levels
of CNOT3 and PRPF31. Sequencing this region is, how-
ever, very complex as it is highly enriched with repetitive
elements—especially Alu repeats, that may act as long-range
regulators of gene expression (Tomilin, 1999). At present,
high-repeat content presents an insurmountable barrier to
sequencing, and currently available commercial sequencing
technologies are not able to read through repeat elements of
greater than 500 bp. After identification of SNPs, it would
be necessary to statistically evaluate the individual risk con-
tributed by each allele, followed by experimental validation
of their functional effect on transcription—a mammoth task!
In summary, linkage data from seven unrelated families
from different ethnic populations have unequivocally shown
that inheritance of the wildtype Chromosome 19 is the major
determinant for the PRPF31 adRP mutation of RP11. When
considered alongside recent work into CNOT3 expression
and function, it can be concluded that the RP11 phenotype
is hypostatic to normal variant alleles of CNOT3, and that re-
cessive coinheritance of the CNOT3 “high-expressing” allele
is one of the major determinants of the disease phenotype in
PRPF31 mutations—a classic example of epistasis affecting a
Mendelian disorder.
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